BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12065740)

  • 1. 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.
    Bidlack JM; Cohen DJ; McLaughlin JP; Lou R; Ye Y; Wentland MP
    J Pharmacol Exp Ther; 2002 Jul; 302(1):374-80. PubMed ID: 12065740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous mu-opioid receptor adaptation by repeated stimulation of kappa-opioid receptor: up-regulation of G-protein activation and antinociception.
    Narita M; Khotib J; Suzuki M; Ozaki S; Yajima Y; Suzuki T
    J Neurochem; 2003 Jun; 85(5):1171-9. PubMed ID: 12753076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
    Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence for the up-regulation of spinal micro-opioid receptor function after repeated stimulation of kappa-opioid receptors in the mouse.
    Narita M; Khotib J; Mizoguchi H; Suzuki M; Ozaki S; Yajima Y; Tseng LF; Suzuki T
    Eur J Neurosci; 2003 Nov; 18(9):2498-504. PubMed ID: 14622150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
    Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
    Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).
    Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1021-7. PubMed ID: 7680715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.
    Vanderah TW; Largent-Milnes T; Lai J; Porreca F; Houghten RA; Menzaghi F; Wisniewski K; Stalewski J; Sueiras-Diaz J; Galyean R; Schteingart C; Junien JL; Trojnar J; Rivière PJ
    Eur J Pharmacol; 2008 Mar; 583(1):62-72. PubMed ID: 18282565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
    Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
    Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
    Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
    Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
    J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2.
    Ozaki S; Narita M; Narita M; Iino M; Miyoshi K; Suzuki T
    Neuroscience; 2003; 116(1):89-97. PubMed ID: 12535942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.